Stephen focuses his practice on mergers & acquisitions, private equity, financings, commercial real estate transactions, and general corporate matters. He has experience representing clients in a variety of industries, including life sciences, technology, manufacturing, wine, health care, insurance, and financial services. He also regularly advises start-ups from the formation of a business entity through a sale of the company. In his commercial real estate practice, Stephen represents parties on all sides of transactions, including buyers, sellers, lenders, borrowers, landlords and tenants.
Prior to joining Mintz, Stephen was an associate in the Business Practice Group of a national law firm, where he worked on transactional and general corporate matters and served as outside general counsel to a Community Development Financial Institution. Earlier, he practiced at two Southern California law firms, focusing primarily on transactions and related matters.
While attending law school, Stephen had internships with the Securities and Exchange Commission, the Department of Homeland Security, and the San Diego County District Attorney's Office. In law school, he served as the articles and comments editor for the University of Miami International and Comparative Law Review. Stephen also received the Dean's Certificate of Achievement Award for his work in the International Business Crimes course.
viewpoints
Preparing a VC-Backed Company for an Exit Event
April 22, 2024 | Alert | By Stephen M. Callegari, Stefan Jović
This alert provides an overview of critical steps companies can take to ensure that an M&A exit event runs smoothly, including ensuring internal agreement on the sale, establishing an M&A team, attending to legal housekeeping matters, and carefully reviewing term sheets received from potential bidders.
News & Press
A Mintz team led by Richard Gervase, Member and Chair of the firm’s Royalty & Revenue Interest Financing Transactions Group, advised global investment firm Sixth Street in a non-dilutive, senior secured credit facility of up to $475 million for Apellis Pharmaceuticals. Apellis received $375 million in funding at close, with ability to access an additional $100 million under the facility at the Company’s option prior to September 2025, subject to the satisfaction of certain conditions.
Recent Insights
A Mintz team led by Richard Gervase, Member and Chair of the firm’s Royalty & Revenue Interest Financing Transactions Group, advised global investment firm Sixth Street in a non-dilutive, senior secured credit facility of up to $475 million for Apellis Pharmaceuticals. Apellis received $375 million in funding at close, with ability to access an additional $100 million under the facility at the Company’s option prior to September 2025, subject to the satisfaction of certain conditions.
